retatrutide type 2 diabetes phase 2 results 2024 2025 Updates in Medicine | Pharmacologic Management of – ADA 🔗 Original article link in bio 🧠 Stepwise approach based on comorbidities and Efficacy and Safety of Retatrutide

At present, no weight loss medication has surpassed the results achieved by retatrutide in clinical research

Frias JP, Deenadayalan S, Erichsen L (2023) Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial

Recognizing these GLP-1 non-responders promptly allows clinicians to adjust treatment strategies before patients experience prolonged periods without meaningful results, potentially leading to frustration and treatment abandonment

Together, we can explore the benefits of semaglutide GLP-1 as part of a comprehensive weight management plan tailored to your unique needs

Side effects are a big deal, ODonnell says

Of these patients, 90,210 (5.2%) had a diagnosis of PCOS